Ligand Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ligand Pharma (LGND) Tops Q2 EPS by 25c, Beats on Revenues; Boosts FY18 EPS/Revenue Outlook
August 6, 2018 4:03 PM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $2.59, $0.25 better than the analyst estimate of $2.34. Revenue for the quarter came in at $90 million versus the consensus estimate of $82.2 million.
The second quarter was punctuated by major positive corporate events that are driving our financial success and highlighting the potential of our business... More
